ImmuCell reports Q3 2024 product sales up 11% to $6M; net loss narrows to $702k

IMMUCELL CORP /DE/

2024-Q3 EPS reported -$0.34 revenue$18,742,040

Product sales $6M in Q3 2024 vs $5.4M in Q3 2023 (+11%); 9-month sales $18.7M (+51% YoY).
Net loss $702k ($0.09/sh) vs $940k ($0.12/sh) in Q3 2023; 9-month loss $2.7M vs $4.6M.
Gross margin improved to 26% of sales in Q3 2024 from 23% in Q3 2023.
EBITDA turned positive to ~$119k in Q3 2024 from ($95k) in Q3 2023.
Cash increased to $3.8M from $979K at Dec 31, 2023; no line of credit drawn.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.